Dren Bio
Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.
$350MPrivate financing
ParticipantActivity from announced rounds
Dren Bio develops antibody therapies for cancer, autoimmune conditions and other serious diseases.
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Develops highly targeted, small molecule medicines for cancer and rare diseases
Develops medicines targeting historically undruggable protein targets in cancer
Latigo Biotherapeutics develops non-opioid pain medicines that target peripheral pain signaling.